loader image
In a clinical trial, TRELSTAR lowered and maintained testosterone below castration levels†1
  • Primary Endpoint Results: Castration levels of serum testosterone (≤ 1.735 nmol/L; equivalent to 50 ng/dL) in patients treated with TRELSTAR 3.75 mg were achieved at Day 29 in 125 of 137 (91.2%) patients and at Day 57 in 97.7% of patients. Maintenance of castration levels of serum testosterone from Day 57 through Day 253 was found in 96.2% of patients treated with TRELSTAR 3.75 mg.
Fewer testosterone breakthroughs than Lupron® in a head‑to‑head study†2,3
  • 4 TRELSTAR escapes occurred within the first 2 months of therapy only
  • 11 leuprolide acetate escapes occurred throughout the entire 9‑month study period
  • TRELSTAR mean T Level over 9 months was 8 ng/dL
Testosterone and PSA suppression regardless of strength†§¶2
  • > 96% reduction in PSA level from baseline to end of study

DOSING SCHEDULES YOU CAN COUNT ON TO HELP MAINTAIN LOW T

TRELSTAR is available in 3 convenient dosage strengths with distinct dosing schedules to meet the individual needs of your patients.‡1

Elderly black man holding a book, with of a large, downward-pointing, yellow arrow behind him.
EVERY 4 WEEKS
TRELSTAR 3.75 mg
Efficacy TRELSTAR 3.75 mg: castration achieved at Day 29 in 125 of 137 (91.2%) patients and at Day 57 in 97.7% of patients. Castration maintained in 96.2% of patients from Day 57 through Day 253.†
Senior white man playing pickleball, with of a large, downward-pointing, green arrow behind him.
EVERY 12 WEEKS
TRELSTAR 11.25 mg
Efficacy TRELSTAR 11.25 mg: castration achieved at Day 29 in 167 of 171 (97.7%) patients. Castration maintained in 94.4% of patients from Day 57 through Day 253.§
Mature black man pulling his luggage, with of a large, downward-pointing, teal arrow behind him.
EVERY 24 WEEKS
TRELSTAR 22.5 mg
Efficacy TRELSTAR 22.5 mg: castration achieved at Day 29 in 97.5% (117 of 120) of patients. Castration maintained in 93.3% of patients from Day 57 to Day 337.

Study Designs

†3.75 mg: Based on a 9-month, multicenter, parallel-group, double-blind, randomized, controlled clinical trial comparing TRELSTAR 3.75 mg to leuprolide acetate (7.5 mg) in patients with advanced (stage C/D) prostate cancer (N = 284). Mean testosterone levels were calculated for Months 2 to 9. The primary efficacy endpoints were both achievement of castration by Day 29 and maintenance of castration from Day 57 through Day 253.1,3

§11.25 mg: In a study of similar design, patients received either TRELSTAR 11.25 mg (N = 174) every 12 weeks for a total of up to 3 doses (maximum treatment period of 253 days) or TRELSTAR 3.75 mg (N = 172) every 28 days for a total of up to 9 doses. The primary efficacy endpoints were both achievement of castration by Day 29 and maintenance of castration from Day 57 through Day 253.1

22.5 mg: In a non-comparative trial, patients received TRELSTAR 22.5 mg (N = 120) every 24 weeks for a total of 2 doses (maximum treatment period of 337 days). The primary efficacy endpoints included achievement of castration by Day 29 and maintenance of castration from Day 57 through Day 337.1

‡Due to different release characteristics, the dosage strengths are not additive and must be selected based upon the desired dosing schedule.

ADT = androgen deprivation therapy; CRPC = castrate-resistant prostate cancer; GnRH = Gonadotropin-releasing hormone; LHRN = luteinizing hormone-releasing hormone; PSA = prostate-specific antigen; T = testosterone

References +- 

  1. TRELSTAR® (triptorelin pamoate for injectable suspension) [prescribing information]. Ewing, NJ: Verity Pharmaceuticals, Inc. April 2024.
  2. Data on file, Verity Pharmaceuticals, Inc.
  3. Heyns CF, Simonin M-P, Grosgurin P, Schall R, Porchet HC. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU International. 2003;92:226‑231.

TSR-144-LPA September 2025

Thank you for visiting.

You are now leaving a Verity website. A link to a non-Verity website does not constitute an endorsement of the products or services offered by the non-Verity website, and Verity is not responsible for the content of any non-Verity website.

TRELSTAR can be ordered directly from our national specialty distributors which provide next business day delivery and other convenient benefits.

Order from AndaMEDS®

Call AndaMEDS at 1.855.468.5649, ext.74453.
Login using your existing TRELSTAR account with AndaMEDS®, or register for a new account, at www.andameds.com.

Order from Besse Medical

Call Besse Medical at 800.543.2111.
Login using your existing TRELSTAR account with with Besse Medical, or register for a new account, at www.besse.com.

Order from CuraScriptSD®

Call CuraScriptSD® at 877.599.7748.
Login using your existing TRELSTAR account with CuraScriptSD® , or register for a new account, at www.curascriptsd.com.

 

Order from Apexus®

For 340B entities order through the prime vendor, Apexus at www.apexus.com.

Healthcare Professionals

The information contained in this website is intended for US Healthcare professionals only.